BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/4/2016 2:42:00 PM | Browse: 1503 | Download: 1737
 |
Received |
|
2016-05-04 08:58 |
 |
Peer-Review Started |
|
2016-05-04 15:42 |
 |
First Decision by Editorial Office Director |
|
|
 |
Return for Revision |
|
2016-05-27 15:38 |
 |
Revised |
|
2016-05-31 02:13 |
 |
Publication Fee Transferred |
|
|
 |
Second Decision by Editor |
|
2016-06-02 10:15 |
 |
Second Decision by Editor-in-Chief |
|
|
 |
Final Decision by Editorial Office Director |
|
2016-06-13 18:14 |
 |
Articles in Press |
|
2016-06-13 18:14 |
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2016-06-26 17:00 |
 |
Publish the Manuscript Online |
|
2016-07-04 14:42 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
|
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Infectious Diseases |
| Manuscript Type |
Editorial |
| Article Title |
Symbiotic chemo- and immuno-therapy for hepatitis B and C viruses
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Babita Agrawal and Rakesh Kumar |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Dr. Rakesh Kumar, Professor, Department of Laboratory Medicine and Pathology, Faculty of Medicine and Dentistry, University of Alberta, 116 St and 85 Ave, Edmonton, AB T6G 2R3, Canada. rkumar@ualberta.ca |
| Key Words |
Hepatitis C virus; Hepatitis B virus; Direct-acting antiviral; Chemotherapy; Immunotherapy |
| Core Tip |
Immune related mechanisms have been shown to eliminate both Hepatitis B and C viruses (HBV and HCV) from chronically infected host cells via non-cytolytic mechanisms. Current direct-acting antivirals against replication of both HBV and HCV are effective and provide significant viral suppression in a relatively short period of time. This time window should be harnessed to target host-mediated immune mechanisms to clear the host of the infection. This strategy would lead to a significant reduction in cost, duration, side effects and development of resistance associated with direct-acting antivirals therapy. In summary, regimens combining chemo- and immuno-therapy must be used in a mutually beneficial manner to eradicate HBV and/or HCV from a host. |
| Publish Date |
2016-07-04 14:42 |
| Citation |
Agrawal B, Kumar R. Symbiotic chemo- and immuno-therapy for hepatitis B and C viruses. World J Gastroenterol 2016; 22(25): 5623-5626
|
| URL |
http://www.wjgnet.com/1007-9327/full/v22/i25/5623.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v22.i25.5623 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.